Erratum to ‘‘intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes’’ (Invest ophthalmol vis sci, (2014), 55, (567–573), 10.1167/iovs.13-13054);Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 1, 2014, Pages 567-573

  Ahn, Seong Joon ^a   Ahn, Jeeyun ^a,b   Park, Sunyoung ^c   Kim, Hyuncheol ^c   Hwang, Duck Jin ^a,d   Park, Ji Hyun ^a   Park, Ji Yeon ^a   Chung, Jae Yong ^e   Park, Kyu Hyung ^a   Woo, Se Joon ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

^c Sogang University   (South Korea)

^d Hangil Eye Hospital   (South Korea)

^e Seoul National University College of Medicine   (South Korea)

Author keywords

Pharmacokinetics; Ranibizumab; Vitrectomy

Indexed keywords

IMMUNOGLOBULIN ANTIBODY; RANIBIZUMAB; VASCULOTROPIN;

ANIMAL EXPERIMENT; AQUEOUS HUMOR; ARTICLE; CENTRIFUGE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; NEW ZEALAND WHITE (RABBIT); NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RETINA; VITRECTOMY; VITREOUS BODY; VITREOUS BODY DETACHMENT;

EID: 84893174095     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-13054     Document Type: Erratum

References (18)

1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
3. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1102-1112.
4. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331:1480-1487.
5. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897-1908.
6. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789-801.
7. Spilsbury K, Garrett KL, Shen WY, Constable IJ, Rakoczy PE. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol. 2000;157:135-144.
8. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179-2182.
9. Christoforidis JB, Williams MM, Wang J, et al. Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy. Retina. 2013; 33:946-952.
10. Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina. 2007;27:1260-1266.
11. Ahn J, Kim H, Woo SJ, et al. Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes. J Ocul Pharmacol Ther. 2013;29:612-618.
12. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005; 46:726-733.
13. Kakinoki M, Sawada O, Sawada T, Saishin Y, Kawamura H, Ohji M. Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys. Invest Ophthalmol Vis Sci. 2012;53:5877-5880.
14. Nomoto H, Shiraga F, Kuno N, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci. 2009;50: 4807-4813.
15. Lee SS, Ghosn C, Yu Z, et al. Vitreous VEGF clearance is increased after vitrectomy. Invest Ophthalmol Vis Sci. 2010; 51:2135-2138.
16. Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina. 2005;25:556-560.
17. Knudsen LL, Dissing T, Hansen MN, Nielsen-Kudsk F. Ocular fluorescein kinetics before and after vitrectomy on swine. Graefes Arch Clin Exp Ophthalmol. 2001;239:832-839.
18. Short BG. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol Pathol. 2008;36:49-62.